NOVAVAX INC (NVAX) Stock Fundamental Analysis

NASDAQ:NVAX • US6700024010

8.735 USD
+0.04 (+0.4%)
Last: Feb 17, 2026, 02:54 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

Taking everything into account, NVAX scores 4 out of 10 in our fundamental rating. NVAX was compared to 521 industry peers in the Biotechnology industry. While NVAX is still in line with the averages on profitability rating, there are concerns on its financial health. NVAX has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year NVAX was profitable.
  • In the past year NVAX has reported a negative cash flow from operations.
  • NVAX had negative earnings in each of the past 5 years.
  • NVAX had negative operating cash flow in 4 of the past 5 years.
NVAX Yearly Net Income VS EBIT VS OCF VS FCFNVAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500M -1B -1.5B

1.2 Ratios

  • The Return On Assets of NVAX (28.96%) is better than 98.08% of its industry peers.
  • NVAX has a Return On Invested Capital of 43.90%. This is amongst the best in the industry. NVAX outperforms 99.42% of its industry peers.
Industry RankSector Rank
ROA 28.96%
ROE N/A
ROIC 43.9%
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NVAX Yearly ROA, ROE, ROICNVAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K 3K 4K 5K

1.3 Margins

  • With an excellent Profit Margin value of 32.10%, NVAX belongs to the best of the industry, outperforming 96.35% of the companies in the same industry.
  • Looking at the Operating Margin, with a value of 39.15%, NVAX belongs to the top of the industry, outperforming 98.46% of the companies in the same industry.
  • Looking at the Gross Margin, with a value of 91.82%, NVAX belongs to the top of the industry, outperforming 93.09% of the companies in the same industry.
Industry RankSector Rank
OM 39.15%
PM (TTM) 32.1%
GM 91.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NVAX Yearly Profit, Operating, Gross MarginsNVAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NVAX is creating value.
  • NVAX has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for NVAX has been increased compared to 5 years ago.
  • NVAX has a worse debt/assets ratio than last year.
NVAX Yearly Shares OutstandingNVAX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
NVAX Yearly Total Debt VS Total AssetsNVAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -2.18, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -2.18, NVAX perfoms like the industry average, outperforming 50.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.18
ROIC/WACC5.08
WACC8.65%
NVAX Yearly LT Debt VS Equity VS FCFNVAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M 600M -600M

2.3 Liquidity

  • A Current Ratio of 2.27 indicates that NVAX has no problem at all paying its short term obligations.
  • NVAX's Current ratio of 2.27 is on the low side compared to the rest of the industry. NVAX is outperformed by 73.13% of its industry peers.
  • A Quick Ratio of 2.24 indicates that NVAX has no problem at all paying its short term obligations.
  • With a Quick ratio value of 2.24, NVAX is not doing good in the industry: 71.02% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.27
Quick Ratio 2.24
NVAX Yearly Current Assets VS Current LiabilitesNVAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 165.04% over the past year.
  • The Revenue has grown by 20.27% in the past year. This is a very strong growth!
  • Measured over the past years, NVAX shows a very strong growth in Revenue. The Revenue has been growing by 105.31% on average per year.
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%

3.2 Future

  • NVAX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.51% yearly.
  • The Revenue is expected to decrease by -13.97% on average over the next years. This is quite bad
EPS Next Y234.29%
EPS Next 2Y34.48%
EPS Next 3Y27.21%
EPS Next 5Y17.51%
Revenue Next Year55.16%
Revenue Next 2Y-25.4%
Revenue Next 3Y-26.75%
Revenue Next 5Y-13.97%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
NVAX Yearly Revenue VS EstimatesNVAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
NVAX Yearly EPS VS EstimatesNVAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -5 -10 -15 -20

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 5.94, the valuation of NVAX can be described as very cheap.
  • 98.85% of the companies in the same industry are more expensive than NVAX, based on the Price/Earnings ratio.
  • NVAX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.19.
  • NVAX is expected to report negative earnings next year, which makes the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE 5.94
Fwd PE N/A
NVAX Price Earnings VS Forward Price EarningsNVAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

  • NVAX's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. NVAX is cheaper than 99.62% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 0.9
NVAX Per share dataNVAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • NVAX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • NVAX's earnings are expected to grow with 27.21% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y34.48%
EPS Next 3Y27.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NVAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NOVAVAX INC

NASDAQ:NVAX (2/17/2026, 2:54:45 PM)

8.735

+0.04 (+0.4%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners61.75%
Inst Owner Change10.09%
Ins Owners0.42%
Ins Owner Change4.42%
Market Cap1.42B
Revenue(TTM)1.06B
Net Income(TTM)341.74M
Analysts73.33
Price Target13.15 (50.54%)
Short Float %34.53%
Short Ratio11.05
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)412.33%
Min EPS beat(2)-3.3%
Max EPS beat(2)827.96%
EPS beat(4)2
Avg EPS beat(4)268.3%
Min EPS beat(4)-58.31%
Max EPS beat(4)827.96%
EPS beat(8)4
Avg EPS beat(8)103.35%
EPS beat(12)7
Avg EPS beat(12)71.73%
EPS beat(16)7
Avg EPS beat(16)-6.56%
Revenue beat(2)2
Avg Revenue beat(2)61.22%
Min Revenue beat(2)58.52%
Max Revenue beat(2)63.92%
Revenue beat(4)4
Avg Revenue beat(4)53.78%
Min Revenue beat(4)2.61%
Max Revenue beat(4)90.08%
Revenue beat(8)5
Avg Revenue beat(8)24.49%
Revenue beat(12)7
Avg Revenue beat(12)22.3%
Revenue beat(16)8
Avg Revenue beat(16)9.73%
PT rev (1m)0.87%
PT rev (3m)-7.94%
EPS NQ rev (1m)-0.56%
EPS NQ rev (3m)-34.76%
EPS NY rev (1m)-3.69%
EPS NY rev (3m)-4.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-16.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.37%
Valuation
Industry RankSector Rank
PE 5.94
Fwd PE N/A
P/S 1.33
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA 0.9
EPS(TTM)1.47
EY16.83%
EPS(NY)-0.32
Fwd EYN/A
FCF(TTM)-2.36
FCFYN/A
OCF(TTM)-2.33
OCFYN/A
SpS6.55
BVpS-0.96
TBVpS-1.66
PEG (NY)0.03
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 28.96%
ROE N/A
ROCE 55.58%
ROIC 43.9%
ROICexc N/A
ROICexgc N/A
OM 39.15%
PM (TTM) 32.1%
GM 91.82%
FCFM N/A
ROA(3y)-23.82%
ROA(5y)-33.12%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA 0.54
Cap/Depr 15.47%
Cap/Sales 0.51%
Interest Coverage 19.68
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.27
Quick Ratio 2.24
Altman-Z -2.18
F-Score6
WACC8.65%
ROIC/WACC5.08
Cap/Depr(3y)158.98%
Cap/Depr(5y)408.8%
Cap/Sales(3y)4.02%
Cap/Sales(5y)5.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)165.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-64.47%
EPS Next Y234.29%
EPS Next 2Y34.48%
EPS Next 3Y27.21%
EPS Next 5Y17.51%
Revenue 1Y (TTM)20.27%
Revenue growth 3Y-15.89%
Revenue growth 5Y105.31%
Sales Q2Q%-16.64%
Revenue Next Year55.16%
Revenue Next 2Y-25.4%
Revenue Next 3Y-26.75%
Revenue Next 5Y-13.97%
EBIT growth 1Y243.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year278.83%
EBIT Next 3Y11.77%
EBIT Next 5YN/A
FCF growth 1Y46.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.24%
OCF growth 3YN/A
OCF growth 5YN/A

NOVAVAX INC / NVAX FAQ

Can you provide the ChartMill fundamental rating for NOVAVAX INC?

ChartMill assigns a fundamental rating of 4 / 10 to NVAX.


What is the valuation status for NVAX stock?

ChartMill assigns a valuation rating of 5 / 10 to NOVAVAX INC (NVAX). This can be considered as Fairly Valued.


How profitable is NOVAVAX INC (NVAX) stock?

NOVAVAX INC (NVAX) has a profitability rating of 4 / 10.


What are the PE and PB ratios of NOVAVAX INC (NVAX) stock?

The Price/Earnings (PE) ratio for NOVAVAX INC (NVAX) is 5.94 and the Price/Book (PB) ratio is -9.06.


Can you provide the financial health for NVAX stock?

The financial health rating of NOVAVAX INC (NVAX) is 3 / 10.